PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24152124-7	2014	The change from baseline in eGFR was positive at all time points during febuxostat treatment and the increase of 2.3 (+-5.6) mL/min/1.73 m2 at 6 months was significant (p = 0.0027).	Febuxostat	72-82	epidermal growth factor receptor	Homo sapiens	28-32	
35260678-7	2022	The interaction between febuxostat treatment and presence of proteinuria in terms of eGFR slope was significant (P for interaction = 0.019).	Febuxostat	24-34	epidermal growth factor receptor	Homo sapiens	85-89	
31335677-10	2019	Also, a significant higher eGFR was found in the febuxostat treated group among CKD stage 3 and 4 patients.	Febuxostat	49-59	epidermal growth factor receptor	Homo sapiens	27-31	
28302902-12	2017	Among the evaluated predictors, multivariate analysis showed that only the lowest eGFR tertile was significantly associated with myopathy in febuxostat users.	Febuxostat	141-151	epidermal growth factor receptor	Homo sapiens	82-86	
28302902-15	2017	CONCLUSIONS: Patients with severely reduced eGFR had higher risk of myopathy with treatment of febuxostat.	Febuxostat	95-105	epidermal growth factor receptor	Homo sapiens	44-48	
30291473-6	2019	The eGFR in the febuxostat group showed an increase from 28.45 to 30.65 mL/min/1.73 m2 at 6 months, while in the allopurinol group, the eGFR decreased from 28.06 to 24.39 mL/min/1.73 m2.	Febuxostat	16-26	epidermal growth factor receptor	Homo sapiens	4-8	
24152124-8	2014	Whereas the eGFR slope was negative during allopurinol treatment, it became positive after the switch to febuxostat.	Febuxostat	105-115	epidermal growth factor receptor	Homo sapiens	12-16	
24152124-9	2014	The change in eGFR slope before and after febuxostat treatment was significant for all patients (p < 0.01), for male patients (p < 0.05), and for patients with a baseline eGFR of <15 mL/min/1.73 m2 (p < 0.05).	Febuxostat	42-52	epidermal growth factor receptor	Homo sapiens	14-18	
24152124-9	2014	The change in eGFR slope before and after febuxostat treatment was significant for all patients (p < 0.01), for male patients (p < 0.05), and for patients with a baseline eGFR of <15 mL/min/1.73 m2 (p < 0.05).	Febuxostat	42-52	epidermal growth factor receptor	Homo sapiens	177-181